{"filings":[{"id":890398,"accession_number":"0001193125-26-259877","cik":1162194,"company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","form_type":"8-K","filed_at":"2026-06-05T21:01:32+00:00","items":["8.01"],"status":"ready","headline":"Standard BioTools regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on June 5, 2026 confirming compliance with Bid Price Requirement.","Previously notified of deficiency on April 20, 2026 due to bid price below $1.00 for 30 consecutive days.","Matter is now closed; no further action required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":427453082.92924523,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":833614,"accession_number":"0001193125-26-255403","cik":1162194,"company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","form_type":"8-K","filed_at":"2026-06-03T20:05:15+00:00","items":["5.02"],"status":"ready","headline":"Standard BioTools grants 500,000 RSUs to CBO Sean Mackay","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Grant of 500,000 restricted stock units approved by Human Capital Committee on May 29, 2026.","RSUs vest 40% on June 20, 2027 and 60% on June 20, 2028, subject to continued service.","Award is under the 2026 Equity Incentive Plan and subject to the 2026 Change of Control and Severance Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":427453082.92924523,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":721812,"accession_number":"0001193125-26-245181","cik":1162194,"company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","form_type":"8-K","filed_at":"2026-05-28T20:05:17+00:00","items":["5.02","9.01"],"status":"ready","headline":"Standard BioTools approves severance plans for CEO, CFO, and CBO through 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2026 Severance Plan for CFO Alex Kim and CBO Sean Mackay: outside COC, 12 months salary, prorated bonus, COBRA subsidy, equity acceleration if terminated by Aug 27, 2026.","During COC: non-CEOs receive 150% of salary plus target bonus lump sum, 18 months COBRA, and full equity vesting.","CEO Michael Egholm covered under 2023 Severance Plan: outside COC, 200% salary over 24 months, 12 months COBRA, outplacement.","During COC: CEO gets 250% of salary plus bonus lump sum, 30 months COBRA, and full equity vesting.","2026 Severance Plan supersedes the 2024 plan; both plans expire August 4, 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":427453082.92924523,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91603,"accession_number":"0001193125-26-206395","cik":1162194,"company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Standard BioTools Q1 revenue $21.1M, up 5% YoY; operating loss cut 54%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing ops $14.6M vs $23.4M YoY; adjusted EBITDA loss $3.1M, 78% improvement.","Revenue $21.1M (+5% YoY); consumables up 35% to $11.0M, instruments down 33% to $4.5M.","Cash & investments $524M at quarter end, plus $25M earnout received post-Q1; total ~$550M.","Full-year 2026 revenue outlook unchanged at $80M-$85M; path to positive adjusted EBITDA exiting 2026.","Operating expenses down 37% to $23.8M, helped by restructuring; non-GAAP gross margin 57.7%."],"consensus_eps_estimate":null,"consensus_eps_actual":0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":21146000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":427453082.92924523,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91602,"accession_number":"0001193125-26-177290","cik":1162194,"company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","form_type":"8-K","filed_at":"2026-04-24T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Standard BioTools receives Nasdaq bid price deficiency notice; 180-day cure period through Oct 19, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice on April 20, 2026: common stock closed below $1.00 for 30 consecutive business days.","Company has 180 calendar days (until October 19, 2026) to regain compliance by maintaining $1.00 closing bid for 10 consecutive days.","If eligible, company may transfer to Nasdaq Capital Market for an additional 180-day cure period, subject to fees and conditions.","Trading under ticker LAB continues uninterrupted; no effect on business operations or SEC reporting.","Company intends to cure, but no assurance of regaining compliance or extension."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":427453082.92924523,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101815,"accession_number":"0001193125-26-067026","cik":1162194,"company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Standard BioTools Q4 rev $23.8M (-4% YoY); FY2025 rev $85.3M (-6%); guides FY2026 $80-85M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net income from continuing ops $13.9M (includes $38.4M deferred tax release) vs net loss $27.2M YoY.","Full-year 2025 net loss $58.8M vs $90.9M; adjusted EBITDA loss $62.6M vs $64.2M.","FY2026 revenue guidance $80-85M; company expects seasonality similar to prior years.","Cash and investments from continuing ops $210.7M at Dec 31, 2025; ~$550M after SomaLogic close on Jan 30, 2026.","Approximately $1 billion in U.S. federal NOL carryforwards available; usage may be limited."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":85331000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":427453082.92924523,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101812,"accession_number":"0001104659-26-010965","cik":1162194,"company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","form_type":"8-K/A","filed_at":"2026-02-05T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Standard BioTools completes sale of SomaScan business to Illumina for ~$363.7M net cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Net cash proceeds of ~$363.7M from sale of SomaLogic and Sengenics entities to Illumina.","Potential earnout payments up to $75M based on 2025/2026 revenue milestones.","Pro forma cash and equivalents of $478.3M as of Sep 30, 2025; gain on sale of $161.9M.","Company retains mass cytometry and microfluidics businesses; no longer party to Collaboration Agreement.","Transaction expenses of $18.4M incurred; $14.8M paid at closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":427453082.92924523,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101814,"accession_number":"0001104659-26-008375","cik":1162194,"company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["2.01","2.02","7.01","9.01"],"status":"ready","headline":"Standard BioTools completes SomaLogic sale to Illumina for up to $425M; holds ~$550M cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Received $350M upfront cash at closing; eligible for up to $75M in earnout payments based on 2025-2026 revenue targets.","Post-close cash and equivalents estimated at ~$550M, excluding potential earnouts, to fund inorganic growth.","Retained mass cytometry and microfluidics businesses; continuing operations on track for positive adjusted EBITDA in 2026.","Company to receive 2% royalty on SOMAmer-based NGS kit sales for 10 years and a co-exclusive license for singleplex assays.","Transaction marks strategic exit from aptamer/proteomics business; management plans disciplined M&A to accelerate growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":427453082.92924523,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101813,"accession_number":"0001193125-26-006996","cik":1162194,"company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Standard BioTools prelim Q4 revenue ~$56M, FY2025 ~$185M; SomaLogic sale on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 combined rev ~$56M (continuing ops ~$24M); FY2025 combined ~$185M (continuing ~$85M).","Exceeded guidance and expectations for both combined and continuing operations.","SomaLogic sale to Illumina on track to close H1 2026; expects ~$550M cash post-close.","Base business on track to positive adjusted EBITDA; positioned for disciplined M&A.","Streamlined operations and improved cost structure exiting year as leaner organization."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":85331000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":427453082.92924523,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118142,"accession_number":"0001193125-25-264693","cik":1162194,"company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Standard BioTools Q3 revenue $19.6M, net loss $31.7M; restructuring targets $40M savings","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue from continuing ops $19.6M, down 11% YoY; net loss $31.7M vs $21.9M loss in Q3 2024.","Adjusted EBITDA loss $16.5M vs $13.7M loss; restructuring plan cuts ~20% workforce for $40M annual savings.","Cash $217M at Sept 30; expects ~$550M cash at close of Illumina transaction in H1 2026.","FY2025 revenue guidance reaffirmed: combined $165-175M, continuing ops $78-83M.","Gross margin 48.5% (GAAP) and 53.5% (non-GAAP), down from prior year due to volume and mix."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":61536000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":427453082.92924523,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134584,"accession_number":"0001193125-25-206150","cik":1162194,"company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","form_type":"8-K","filed_at":"2025-09-17T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Standard BioTools cuts 15% of workforce, expects $7.5M in restructuring costs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company commenced restructuring plan reducing global workforce by approx. 15%.","Expects restructuring costs of ~$7.5M, primarily for cash severance and termination benefits.","Reduction aimed at improving operational efficiency and aligning costs with revenue projections.","Costs expected to be paid over the next several months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":427453082.92924523,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134583,"accession_number":"0000950170-25-112662","cik":1162194,"company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Standard BioTools to consolidate R&D to Singapore, reduce US workforce, expects $3.6M in costs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Consolidates South San Francisco R&D into Singapore facility to co-locate with manufacturing.","Reduction-in-force of certain US R&D employees, including management team members.","Estimated total expenses of ~$3.6M, including ~$0.9M non-cash share-based award vesting.","Restructuring costs expected to be payable over the next several months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":427453082.92924523,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134582,"accession_number":"0000950170-25-106636","cik":1162194,"company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Standard BioTools Q2 revenue $21.8M, net loss improves; sells SomaLogic to Illumina for up to $425M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 continuing ops revenue $21.8M, down 3% YoY; net loss $17.7M vs $25.4M loss a year ago.","Consumables revenue up 18% YoY to $10.5M; instruments down 26% to $5.2M; services down 8% to $6.1M.","Adjusted EBITDA loss $16.1M vs $17.4M; targeting adjusted EBITDA breakeven in 2026.","Announced sale of SomaLogic to Illumina for up to $425M cash plus royalties; expected close H1 2026.","FY2025 revenue outlook: combined $165-175M; continuing ops $78-83M; cash $239.7M, expects ≥$550M post-close."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":41984000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":427453082.92924523,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134581,"accession_number":"0000950170-25-101439","cik":1162194,"company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Standard BioTools grants 3M RSUs to CEO Egholm, 1.5M to CFO Kim; CFO bonus target raised to 80%","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO Michael Egholm granted 3,000,000 RSUs; 25% vest Aug 1, 2026, then 25% annually over 3 years.","CFO Alex Kim granted 1,500,000 RSUs; 40% vest Jul 20, 2026, 60% vest Jul 20, 2027.","CFO Kim's annual bonus target increased to 80% of base salary, retroactive to Jan 1, 2025.","Awards are retention-focused under the 2011 Equity Incentive Plan and change-of-control severance plans."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":427453082.92924523,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151450,"accession_number":"0001104659-25-061438","cik":1162194,"company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Standard BioTools sells SomaLogic to Illumina for up to $425M; expects $550M cash at close","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront cash payment of $350M at closing plus up to $75M in near-term earnout milestones for total up to $425M.","Retains 2% royalty on Illumina Protein Prep NGS kit sales for 10 years and co-exclusive Single SOMAmer rights.","Transaction simplifies operating structure; expects to achieve adjusted EBITDA break-even post-close.","Pro forma cash & equivalents of at least $550M at close to fund inorganic growth strategy.","Expected close in H1 2026, subject to HSR clearance and other customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":427453082.92924523,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151449,"accession_number":"0000950170-25-088519","cik":1162194,"company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Stockholders approve 17.4M share increase to equity plan; Hibbs and Witney elected directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2011 Equity Incentive Plan, increasing share reserve by 17.4 million shares.","Elected Kathy Hibbs and Frank Witney as Class III directors to serve until 2028 annual meeting.","Advisory vote on 2024 executive compensation approved: 241.1M for, 4.0M against.","Ratified PricewaterhouseCoopers as independent auditor for fiscal 2025.","Approximately 86% of outstanding shares (326.9M of 379.8M) were represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":427453082.92924523,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151448,"accession_number":"0000950170-25-064439","cik":1162194,"company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Standard BioTools Q1 2025 revenue $40.8M (-10% YoY); net loss $26.0M, adj EBITDA loss $16.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["First-quarter revenue $40.8M, down 10% YoY; consumables -16%, instruments +24%, services -16%.","Net loss $26.0M improved 19% YoY ($32.2M); adjusted EBITDA loss $16.9M improved 29%.","Non-GAAP gross margin 53.2%, down from 56.2% in Q1 2024 due to volume, mix, and pricing.","Cash & equivalents $260.7M, no material debt; FY2025 revenue outlook reaffirmed at $165-175M.","Operating expenses fell 38% YoY to $52.7M, driven by merger cost synergies and SBS productivity gains."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":40795000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":427453082.92924523,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170327,"accession_number":"0000950170-25-027712","cik":1162194,"company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Standard BioTools reports Q4 pro forma revenue $46.7M, down 9% YoY; 2025 guidance $165-175M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 pro forma revenue $46.7M (down 9% YoY); full year $175.1M (down 9% YoY).","Q4 net loss $34.1M improved from $55.3M loss; adjusted EBITDA loss $18.4M (34% improvement).","Achieved $90M in operational cost synergies, exceeding original target by $10M; cash $295M, no debt.","2025 revenue guidance $165M-$175M, citing anticipated NIH funding pressure and no tariff impact.","Full year consumables revenue up 18% YoY; instruments down 27%; services down 17%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":174432000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":427453082.92924523,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170326,"accession_number":"0001104659-25-002848","cik":1162194,"company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Standard BioTools reports preliminary FY2024 revenue ~$174M; Q4 ~$46.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2024 revenue approximately $46.5 million.","Full year 2024 revenue approximately $174 million, at top end of revised guidance.","CEO cites industry-wide headwinds and progress reducing operating expenses via SBS.","Company to discuss 2025 outlook when reporting final Q4/FY results later in Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":174432000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":427453082.92924523,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170325,"accession_number":"0000950170-25-004155","cik":1162194,"company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Standard BioTools CCO Jeremy Davis to depart Feb 1, 2025; severance details disclosed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeremy Davis will step down as Chief Commercial Officer effective February 1, 2025, by mutual agreement.","Severance includes 12 months' base salary continuation of $441,000 plus 2024 bonus of $169,785.","Pro-rated target bonus of $21,264.65 and COBRA premium payments through Feb 2026 or earlier.","Outstanding unvested equity awards will receive 100% vesting acceleration, with performance-based awards at target.","Severance agreement to be filed with Q1 2025 10-Q; no replacement yet announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":427453082.92924523,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187324,"accession_number":"0000950170-24-139051","cik":1162194,"company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Standard BioTools to pay $890,000 to settle attorneys' fees in stockholder disclosure lawsuit","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Standard BioTools will pay $890,000 to plaintiffs' counsel to resolve mootness fee application in class action over proxy disclosures.","Settlement does not constitute admission of wrongdoing; SomaLogic denies all allegations.","Delaware Court entered order requiring notice via 8-K; court did not pass judgment on reasonableness of payment.","Lawsuit filed Dec 2023 alleged false/misleading proxy in SomaLogic merger; supplemental disclosures mooted claims."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":427453082.92924523,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187323,"accession_number":"0000950170-24-122823","cik":1162194,"company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Standard BioTools appoints Alex Kim as CFO; COO role eliminated","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alex Kim appointed full-time CFO effective Nov 11, 2024; was interim CFO since Sept 1, 2024.","Kim previously served as COO; that position will be vacated after his CFO appointment.","Kim is a co-founder with nearly 30 years experience in healthcare and life sciences.","Jonathan Mickelsen named VP & Chief Accounting Officer.","No additional compensation for Kim in CFO role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":427453082.92924523,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187322,"accession_number":"0000950170-24-119014","cik":1162194,"company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Standard BioTools Q3 revenue $45M, net loss improves 34.6% YoY; reaffirms FY2024 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2024 revenue $45.0M (-5% YoY pro forma); net loss $26.9M improved from $41.2M loss YoY.","Adjusted EBITDA loss $14.2M vs $28.2M loss YoY, a 49.6% improvement; merger synergies $80M on track for 2025.","Consumables revenue up 13% to $14.0M; Instruments down 42% to $5.6M due to capital constraints, especially China.","FY2024 revenue guidance reaffirmed at $170M-$175M; path to adjusted EBITDA break-even in 2026.","Cash and short-term investments $367.6M; gross margin 51.7% (42.5% YoY), non-GAAP gross margin 56.9%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":127714000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":427453082.92924523,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203831,"accession_number":"0001104659-24-097368","cik":1162194,"company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","form_type":"8-K","filed_at":"2024-09-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Standard BioTools updates investor presentation; no material changes disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed updated investor presentation dated September 5, 2024 under Item 7.01.","Presentation intended for general corporate use; available on company website.","No new financial guidance, M&A, or leadership changes in the filing.","Only presentation cover page excerpt provided; full content not reviewable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":427453082.92924523,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203830,"accession_number":"0001104659-24-095596","cik":1162194,"company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","form_type":"8-K","filed_at":"2024-08-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Standard BioTools Adopts 2024 Change of Control and Severance Plan for Key Executives","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Plan provides 12 months base salary and full equity vesting for non-COC termination for COO Kim, CLO Gallagher, CCO Davis, and others.","For termination during Change of Control Period: 150% lump-sum of base salary plus bonus, 18-month COBRA, and immediate full equity vesting.","Plan supersedes the 2023 severance plan and covers eight named executives including SVP King, SVP Abou-Sayed, and CHRO Jensen.","Plan term runs until August 4, 2026; CEO Michael Egholm remains covered under separate 2023 plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":427453082.92924523,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203829,"accession_number":"0001104659-24-084362","cik":1162194,"company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Standard BioTools CFO Jeffrey Black resigns effective Aug 31; COO Alex Kim named interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeffrey Black resigns as CFO effective Aug 31, 2024 to accept opportunity at another public company; no disagreement.","Alex Kim, current COO and co-founder, appointed interim CFO starting Sep 1, 2024; permanent search underway.","Sean Mackay, former IsoPlexis CEO, named Chief Business Officer with expanded responsibilities across product management, marketing, and IR."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":427453082.92924523,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203828,"accession_number":"0000950170-24-088578","cik":1162194,"company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Standard BioTools Q2 revenue $37.2M, net loss $45.7M; FY2024 guidance cut to $170-175M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $37.2M (pro forma combined -23% YoY); net loss $45.7M; adjusted EBITDA loss $31.0M.","FY2024 revenue guidance reduced to $170-$175M from prior expectation; cites weaker SomaScan services and capital spending slowdown.","Accelerated merger synergy target: $80M cost reductions expected operationalized by end of 2024, a year ahead of plan.","Repurchased ~11.3M shares in Q2 for ~$29M at avg $2.57/share; cash position $396M.","Revenue decline primarily from timing of large customer projects in Europe and constrained capital purchase environment."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":82745000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":427453082.92924523,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203827,"accession_number":"0001104659-24-076823","cik":1162194,"company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Standard BioTools shareholders approve 19.125M share increase to equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to increase shares reserved under 2011 Equity Incentive Plan by 19,125,000 approved.","79.19% of outstanding shares (292,959,945 votes) represented; all director nominees elected.","Advisory say-on-pay passed with ~87% of votes cast (200.8M for, 29.0M against).","Ratification of PricewaterhouseCoopers as auditor for FY2024 approved (291.6M votes for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":427453082.92924523,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220438,"accession_number":"0001104659-24-067384","cik":1162194,"company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Madryn withdraws director nominations for Standard BioTools annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Madryn Asset Management affiliate irrevocably withdrew its March 15 notice to nominate directors and submit a business proposal at the 2024 annual meeting.","Company will distribute a revised proxy card to stockholders reflecting the withdrawal.","No financial terms, governance changes, or operational updates were disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":427453082.92924523,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220437,"accession_number":"0000950170-24-055791","cik":1162194,"company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Standard BioTools Q1: pro forma revenue $46.2M (+2% YoY), gross margin 49.2%, cash $464M, reaffirms FY outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["As-reported revenue $45.5M (+81% YoY from SomaLogic merger); pro forma combined revenue $46.2M (+2% YoY).","Pro forma gross margin 49.2% (up 276 bps), non-GAAP gross margin 56.3% (up 300 bps). Operating expenses fell $21M to $75.8M.","Cash, equivalents, restricted cash & short-term investments $463.6M. Repurchased 4.1M shares for $11M; converted all Series B preferred to common.","Reaffirmed FY2024 revenue guidance $200-205M; targeting cash flow positive in FY2026. $50M of $80M cost synergies expected by year-end 2024.","SomaScan services, authorized sites, Illumina early access contributed over $24M (+21% YoY); instrument revenue declined 12% on capex headwinds."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":45540000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":427453082.92924523,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220436,"accession_number":"0001104659-24-051640","cik":1162194,"company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","form_type":"8-K","filed_at":"2024-04-25T23:59:59+00:00","items":["2.05","7.01","9.01"],"status":"ready","headline":"Standard BioTools cuts 10% of workforce, targets $45-50M annual savings in FY2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reduction-in-force of ~10% including senior management positions eliminated after SomaLogic merger.","Expected annualized operating expense savings of $45-$50 million in fiscal 2025, majority in H2 2024.","Restructuring costs of $10-$11 million, including $4 million non-cash share-based vesting expenses.","Closure of San Diego R&D facility; prioritization of R&D spend to improve operational efficiency.","Q1 2024 earnings call scheduled for May 8, 2024 at 1:30 p.m. PDT."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":427453082.92924523,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240079,"accession_number":"0001104659-24-035297","cik":1162194,"company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","form_type":"8-K","filed_at":"2024-03-18T23:59:59+00:00","items":["1.01","3.02","5.02","5.03","7.01","9.01"],"status":"ready","headline":"Standard BioTools exchanges all Series B Preferred for ~93M common shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exchanged 127,780 Series B-1 and 127,779 Series B-2 shares for 92,930,553 common shares at $2.75 per share.","Eliminated ~$250M liquidation preference and all Series B preferred governance rights, including change-in-control put.","Incremental 17.8M shares issued vs. original $3.40 conversion price; dilution <5% on as-issued basis.","Outstanding common shares now approx. 382.5M; no Series B shares remain after closing.","Directors Eli Casdin and Fenel Eloi assigned to Class I (term 2026) and Class II (term 2024) respectively."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":427453082.92924523,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240078,"accession_number":"0000950170-24-022060","cik":1162194,"company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Standard BioTools FY2023 revenue $106M (+9%); Q4 gross margin 59.6%; SomaLogic merger closed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2023 revenue $106.3M (+9% YoY); Q4 revenue $28.2M (+4%); instrument sales +46% for FY.","Non-GAAP gross margin 60.1% for FY2023 (+900 bps YoY); net loss $74.7M.","Non-GAAP adjusted EBITDA loss improved $34M to $34.7M; operating cash use down 53%.","Combined pro forma 2023 revenue ~$192M; pro forma cash $565M (incl. SomaLogic's $449.8M).","Merger with SomaLogic closed Jan 5, 2024; integration underway; CEO cites disciplined execution."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":106340000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":427453082.92924523,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}